EHA 2016 | What is in the future for T-cell lymphoma?
Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY discusses the positive trend in the research for treating T-cell lymphoma. The last 5 years have been extraordinary with the development of HDAC inhibitors, with three approved world wide – vorinostat and romidepsin in the US and chidamide in China. Dr O’Connor mentions how he was sceptical about adding these new drugs to CHOP backbones. He also discusses the presentation at ASH which outlined studies investigating combinations of pralatrexate and romidepsin, and combinations of hypomethylating agents and HDAC inhibitors. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up